AR110351A1 - COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa - Google Patents

COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Info

Publication number
AR110351A1
AR110351A1 ARP170103473A ARP170103473A AR110351A1 AR 110351 A1 AR110351 A1 AR 110351A1 AR P170103473 A ARP170103473 A AR P170103473A AR P170103473 A ARP170103473 A AR P170103473A AR 110351 A1 AR110351 A1 AR 110351A1
Authority
AR
Argentina
Prior art keywords
alkyl
ifna
heteroarilo
phosphinoxide
rented
Prior art date
Application number
ARP170103473A
Other languages
English (en)
Inventor
David S Weinstein
John V Duncia
Zili Xiao
Michael G Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR110351A1 publication Critical patent/AR110351A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Abstract

Compuestos o un estereoisómero o una sal de aquellos aceptable desde el punto de vista farmacéutico, útiles para la modulación de IL-12, IL-23 y/o IFNa que actúan en Tyk-2 para generar la inhibición de la transducción de señal. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1), en donde: X es -N- o -CH-; Y es -N- o -CH-; R¹ es CD₃, C₁₋₃ alquilo o C₃₋₆ cicloalquilo; R² es CO-C₃₋₆ cicloalquilo, C₅₋₈ arilo o un heterociclilo de 5 - 7 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, sustituidos con 0 - 4 R²ᵃ; R²ᵃ es, independientemente de cada caso, hidrógeno, halógeno, C₁₋₆ alquilo, C₁₋₆ alcoxi, C₃₋₆ cicloalquilo, halo-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, C₅₋₈ arilo o un heterociclilo de 5 - 7 miembros que contiene 1 - 4 heteroátomos seleccionados de N, O y S, en donde dicho arilo o heterociclilo se sustituye con 0 - 2 Rᵃ; Rᵃ es hidrógeno, halógeno o C₁₋₄ alquilo; R³ es P(O)-(C₁₋₄ alquilo)₂; o un estereoisómero o una sal de aquel aceptable desde el punto de vista farmacéutico.
ARP170103473A 2016-12-13 2017-12-12 COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa AR110351A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662433470P 2016-12-13 2016-12-13

Publications (1)

Publication Number Publication Date
AR110351A1 true AR110351A1 (es) 2019-03-20

Family

ID=60888685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103473A AR110351A1 (es) 2016-12-13 2017-12-12 COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Country Status (10)

Country Link
US (1) US10294256B2 (es)
EP (1) EP3555111B1 (es)
JP (1) JP7046092B2 (es)
KR (1) KR102602558B1 (es)
CN (1) CN110267964B (es)
AR (1) AR110351A1 (es)
ES (1) ES2907008T3 (es)
MA (1) MA48602A (es)
TW (1) TW201827423A (es)
WO (1) WO2018111787A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091269A1 (ru) 2017-11-21 2020-08-07 Бристол-Маерс Сквибб Компани Сульфон-, пиридин-, алкил-, амид-замещенные гетероарильные соединения
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
EA029131B1 (ru) * 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Фосфорсодержащие производные в качестве ингибиторов киназы
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP5957537B2 (ja) * 2011-12-21 2016-07-27 ビオタ ヨーロッパ リミテッドＢｉｏｔａ Ｅｕｒｏｐｅ Ｌｔｄ 複素環式ウレア化合物
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
AR093403A1 (es) * 2012-11-08 2015-06-03 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
WO2014181287A1 (en) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
TWI582077B (zh) * 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
EP2947460A1 (en) * 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists

Also Published As

Publication number Publication date
JP7046092B2 (ja) 2022-04-01
EP3555111B1 (en) 2022-01-26
EP3555111A1 (en) 2019-10-23
ES2907008T3 (es) 2022-04-21
WO2018111787A1 (en) 2018-06-21
CN110267964B (zh) 2022-05-03
JP2020502268A (ja) 2020-01-23
US10294256B2 (en) 2019-05-21
KR20190091536A (ko) 2019-08-06
KR102602558B1 (ko) 2023-11-14
MA48602A (fr) 2020-03-18
US20180162889A1 (en) 2018-06-14
CN110267964A (zh) 2019-09-20
TW201827423A (zh) 2018-08-01

Similar Documents

Publication Publication Date Title
AR110351A1 (es) COMPUESTOS DE HETEROARILO SUSTITUIDOS CON FOSFINÓXIDO ALQUILAMIDA COMO MODULADORES DE RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AR119454A2 (es) COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO
AR119761A2 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
EA201591491A1 (ru) Соединения тетрагидропирролотиазина
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201790328A1 (ru) Диоксолановые аналоги уридина для лечения рака
EA201790922A1 (ru) Ингибиторы бромодомена
AR102171A1 (es) Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma
CY1122563T1 (el) ΑΜΙΔΟΫΠΟΚΑΤΕΣΤΗΜΕΝΑ ΘΕΙΑΖΟΛΙΑ ΩΣ ΔΙΑΜΟΡΦΩΤΕΣ RORγt
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
CO2020006139A2 (es) Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
EA201790343A1 (ru) Способ получения сульфамидных производных пиримидина
EA201891562A2 (ru) ТРИФТОРМЕТИЛОВЫЕ СПИРТЫ КАК МОДУЛЯТОРЫ RORγt
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
AR109706A1 (es) INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g
AR098037A1 (es) Derivados de piperazina y su uso como medicamento
AR098319A1 (es) Profármacos de antagonista de nmda
AR099300A1 (es) Hexahidrofuropirroles como inhibidores de pde1

Legal Events

Date Code Title Description
FB Suspension of granting procedure